BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 17023095)

  • 21. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection.
    Klugman KP; Madhi SA; Huebner RE; Kohberger R; Mbelle N; Pierce N;
    N Engl J Med; 2003 Oct; 349(14):1341-8. PubMed ID: 14523142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity of a heptavalent pneumococcal conjugate vaccine in Apache and Navajo Indian, Alaska native, and non-native American children aged <2 years.
    Miernyk KM; Parkinson AJ; Rudolph KM; Petersen KM; Bulkow LR; Greenberg DP; Ward JI; Brenneman G; Reid R; Santosham M
    Clin Infect Dis; 2000 Jul; 31(1):34-41. PubMed ID: 10913393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers.
    Goldblatt D; Southern J; Ashton L; Richmond P; Burbidge P; Tasevska J; Crowley-Luke A; Andrews N; Morris R; Borrow R; Cartwright K; Miller E
    Pediatr Infect Dis J; 2006 Apr; 25(4):312-9. PubMed ID: 16567982
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary and booster salivary antibody responses to a 7-valent pneumococcal conjugate vaccine in infants.
    Choo S; Zhang Q; Seymour L; Akhtar S; Finn A
    J Infect Dis; 2000 Oct; 182(4):1260-3. PubMed ID: 10979930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease.
    Meng C; Lin H; Huang J; Wang H; Cai Q; Fang L; Guo Y
    Microb Pathog; 2009 Sep; 47(3):151-6. PubMed ID: 19467319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children.
    Kilpi T; Ahman H; Jokinen J; Lankinen KS; Palmu A; Savolainen H; Grönholm M; Leinonen M; Hovi T; Eskola J; Käyhty H; Bohidar N; Sadoff JC; Mäkelä PH;
    Clin Infect Dis; 2003 Nov; 37(9):1155-64. PubMed ID: 14557958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pneumococcal conjugate vaccine primes for polysaccharide-inducible IgG2 antibody response in children with recurrent otitis media acuta.
    Breukels MA; Rijkers GT; Voorhorst-Ogink MM; Zegers BJ; Sanders LA
    J Infect Dis; 1999 May; 179(5):1152-6. PubMed ID: 10191217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and immunological memory induced by a 7-valent pneumococcal CRM197 conjugate vaccine in symptomatic HIV-1 infected children.
    Spoulou VI; Tsoumas DL; Papaevangelou VG; Mostrou GI; Theodoridou MC
    Vaccine; 2005 Nov; 23(46-47):5289-93. PubMed ID: 16054732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A 5-year longitudinal follow-up study of serological responses to 23-valent pneumococcal polysaccharide vaccination among patients with HIV infection who received highly active antiretroviral therapy.
    Hung CC; Chang SY; Su CT; Chen YY; Chang SF; Yang CY; Liu WC; Wu CH; Chang SC
    HIV Med; 2010 Jan; 11(1):54-63. PubMed ID: 19659943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Introduction of pneumococcal conjugate vaccine into the public immunization program in South Africa: translating research into policy.
    Madhi SA; Cohen C; von Gottberg A
    Vaccine; 2012 Sep; 30 Suppl 3():C21-7. PubMed ID: 22939016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine.
    Miiro G; Kayhty H; Watera C; Tolmie H; Whitworth JA; Gilks CF; French N
    J Infect Dis; 2005 Nov; 192(10):1801-5. PubMed ID: 16235180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 Feb; 57(6):144-8. PubMed ID: 18272956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serotype-specific hyporesponsiveness to pneumococcal conjugate vaccine in infants carrying pneumococcus at the time of vaccination.
    Väkeväinen M; Soininen A; Lucero M; Nohynek H; Auranen K; Mäkelä PH; Williams G; Käyhty H;
    J Pediatr; 2010 Nov; 157(5):778-83.e1. PubMed ID: 20547399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term effect of pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae--and associated interactions with Staphylococcus aureus and Haemophilus influenzae colonization--in HIV-Infected and HIV-uninfected children.
    Madhi SA; Adrian P; Kuwanda L; Cutland C; Albrich WC; Klugman KP
    J Infect Dis; 2007 Dec; 196(11):1662-6. PubMed ID: 18008250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections.
    Zangeneh TT; Baracco G; Al-Tawfiq JA
    Expert Rev Vaccines; 2011 Mar; 10(3):345-53. PubMed ID: 21434802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of community-wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3 years of age: a cross-sectional study in a high-risk population.
    Millar EV; O'Brien KL; Watt JP; Bronsdon MA; Dallas J; Whitney CG; Reid R; Santosham M
    Clin Infect Dis; 2006 Jul; 43(1):8-15. PubMed ID: 16758412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cross-sectional study of nasopharyngeal carriage of Streptococcus pneumoniae in human immunodeficiency virus-infected adults in the conjugate vaccine era.
    Onwubiko C; Swiatlo E; McDaniel LS
    J Clin Microbiol; 2008 Nov; 46(11):3621-5. PubMed ID: 18845823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of two schedules of two-dose priming with the ten-valent pneumococcal conjugate vaccine in Nepalese children: an open-label, randomised non-inferiority controlled trial.
    Kandasamy R; Gurung M; Thorson S; Yu LM; Galal U; Voysey M; Kelly S; Wahl B; Berbers G; Finnegan K; Ansari I; Paudel K; Murdoch DR; O'Brien KL; Kelly DF; Goldblatt D; Shrestha S; Pollard AJ
    Lancet Infect Dis; 2019 Feb; 19(2):156-164. PubMed ID: 30635252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and safety of heptavalent conjugate vaccine against Streptococcus pneumoniae in pre-term Polish infants.
    Szynczewska E; Chlebna-Sokół D
    Vaccine; 2011 Sep; 29(40):7107-13. PubMed ID: 21803093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults.
    Lesprit P; Pédrono G; Molina JM; Goujard C; Girard PM; Sarrazin N; Katlama C; Yéni P; Morineau P; Delfraissy JF; Chêne G; Lévy Y;
    AIDS; 2007 Nov; 21(18):2425-34. PubMed ID: 18025879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.